by Madaline Spencer and Joe Haddad | Apr 9, 2026
The US Food and Drug Administration (FDA) has approved Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory (R/R) mantle cell lymphoma (MCL). MCL is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the...
by Madaline Spencer and Joe Haddad | Mar 27, 2026
The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage 3 or 4 classical Hodgkin lymphoma (cHL). The approval...
by Madaline Spencer and Joe Haddad | Mar 17, 2026
Amel Karaa, MD, Genetics and General Metabolism, Director of the Mitochondrial Disease Program at Massachusetts General Hospital, discusses the PRIZM clinical trial of zagociguat in patients with MELAS. MELAS, or Mitochondrial Encephalomyopathy, Lactic...
by Madaline Spencer and Joe Haddad | Mar 13, 2026
Kristin McKay, President and Executive Director of Project Alive, discusses the real-world perspective on daily challenges of living with mucopolysaccharides II (MPS II). MPS II is an inherited disorder of carbohydrate metabolism that occurs almost exclusively...
by Madaline Spencer and Joe Haddad | Oct 30, 2025
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) for the treatment of relapsed/refractory acute myeloid leukemia (AML). The indication is for adult and pediatric patients one year of age and older with a susceptible nucleophosmin 1 (NPM1)...
